Israel’s Prolor Biotech announced positive results in a pre-clinical trial of MOD-6030, its long-acting obesity/Type II diabetes drug. In the laboratory, the drug reduced blood glucose levels, increased insulin sensitivity, and reduced cholesterol levels compared to a placebo.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000741847&fid=1725